Prognostic value of intraductal carcinoma subtypes and postoperative radiotherapy for localized prostate cancer

Abstract Background Intraductal carcinoma of the prostate cancer (IDC-P), as a specific pathological type in prostate cancer which usually implies a poor prognosis. IDC-P morphology can be divided into two subtypes: Pattern 1, sieve like or loose cribriform structures; Pattern 2, solid or dense crib...

Full description

Saved in:
Bibliographic Details
Main Authors: Fang Cao, Qing Li, Tianyu Xiong, Yingjie Zheng, Tian Zhang, Mulan Jin, Liming Song, Nianzeng Xing, Yinong Niu
Format: Article
Language:English
Published: BMC 2025-01-01
Series:BMC Urology
Subjects:
Online Access:https://doi.org/10.1186/s12894-025-01690-1
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832585360334389248
author Fang Cao
Qing Li
Tianyu Xiong
Yingjie Zheng
Tian Zhang
Mulan Jin
Liming Song
Nianzeng Xing
Yinong Niu
author_facet Fang Cao
Qing Li
Tianyu Xiong
Yingjie Zheng
Tian Zhang
Mulan Jin
Liming Song
Nianzeng Xing
Yinong Niu
author_sort Fang Cao
collection DOAJ
description Abstract Background Intraductal carcinoma of the prostate cancer (IDC-P), as a specific pathological type in prostate cancer which usually implies a poor prognosis. IDC-P morphology can be divided into two subtypes: Pattern 1, sieve like or loose cribriform structures; Pattern 2, solid or dense cribriform structures. The purpose of the study is to identify the impact of IDC-P and its subtypes on the prognosis of patients undergoing post-operative radiotherapy (PORT) after radical prostatectomy (RP) due to localized prostate cancer(PCa). Methods We performed a retrospective study of patients with localized PCa treated by RP followed by PORT or not. Patients with localized PCa who underwent RP from August 2013 to December 2020 were included in this study. Inclusion criteria: post-operative PSA dropped to less than 0.1 ng/ml after RP, had at least 1 poor prognostic risk factor (including high Gleason’s grouping; positive surgical margins; seminal vesicle invasion; extraprostatic extension; and lympho-vascular invasion), and were eligible for adjuvant radiotherapy.; In this study, patients who underwent salvage radiotherapy after RP due to biochemical recurrence (two consecutive PSA > 0.2 ng/ml) were also included, but not patients with persistent postoperative PSA > 0.1 ng/ml. Exclusion criteria: patients using other types of therapy prior to biochemical recurrence. Screening cases with pathological results of intraductal carcinoma, subtyping was completed by a pathologist, grouped by intraductal carcinoma (+/-; pattern 1/ 2) and treatment regimen (RP + PORT / RP only), Kaplan-Meier curves were plotted based on the time to biochemical recurrence-free and overall survival of the patients, and Cox regression analyses were performed. Finally, based on the results of Cox regression analysis, we initially predicted the probability of biochemical recurrence and death of the patients by plotting the nomogram. Results A total of 139 patients were included in this study with a median follow-up of 61.5 months. K-M curves showed that patients with “IDC-P (+) RP only” had the worst prognosis; patients with IDC-P could have a survival benefit after receiving PORT; whereas patients with non-intraductal carcinoma had a better prognosis than the above patients with or without PORT. In addition, patients with IDC-P(+) pattern 2 were more likely to experience biochemical recurrence and death. Multivariate Cox regression analysis showed that pattern 2 was a risk factor for biochemical recurrence and death. Other BCR-related risk factors in the research: Gleason grading group 5 (HR = 3.343, 95% CI: 1.616–6.916, P = 0.001), PM (HR = 2.124, 95% CI: 1.044–4.320,P = 0.038) and PORT (HR = 0.266, 95%CI: 0.109–0.647, P = 0.004). Other OS-related risk factors in the research: Grading group 5 (HR = 3.642, 95%CI:1.475–8.991, P = 0.005), SVI (HR = 2.522, 95% CI: 1.118–5.691, P = 0.026) and PORT (HR = 0.319, 95%CI: 0.107–0.949, P = 0.040). Conclusion Patients suffering from localized prostate cancer with IDC-P(+), especially IDC-P pattern 2, are more susceptible to biochemical recurrence and death after radical prostatectomy. While postoperative radiotherapy can alleviate the negative prognostic impact from IDC-P. It is implied that IDC-P can also be an indicator to be considered in PORT decision making to some extent.
format Article
id doaj-art-759108a890d943fb8eb67e06379e8faa
institution Kabale University
issn 1471-2490
language English
publishDate 2025-01-01
publisher BMC
record_format Article
series BMC Urology
spelling doaj-art-759108a890d943fb8eb67e06379e8faa2025-01-26T12:54:10ZengBMCBMC Urology1471-24902025-01-0125111210.1186/s12894-025-01690-1Prognostic value of intraductal carcinoma subtypes and postoperative radiotherapy for localized prostate cancerFang Cao0Qing Li1Tianyu Xiong2Yingjie Zheng3Tian Zhang4Mulan Jin5Liming Song6Nianzeng Xing7Yinong Niu8Department of Urology, Beijing Chaoyang Hospital, Capital Medical UniversityDepartment of Pathology, Beijing Chaoyang Hospital, Capital Medical UniversityDepartment of Urology, Beijing Chaoyang Hospital, Capital Medical UniversityDepartment of Radiotherapy, Beijing Chaoyang Hospital, Capital Medical UniversityDepartment of Radiotherapy, Beijing Chaoyang Hospital, Capital Medical UniversityDepartment of Pathology, Beijing Chaoyang Hospital, Capital Medical UniversityDepartment of Urology, Beijing Chaoyang Hospital, Capital Medical UniversityDepartment of Urology, Beijing Chaoyang Hospital, Capital Medical UniversityDepartment of Urology, Beijing Chaoyang Hospital, Capital Medical UniversityAbstract Background Intraductal carcinoma of the prostate cancer (IDC-P), as a specific pathological type in prostate cancer which usually implies a poor prognosis. IDC-P morphology can be divided into two subtypes: Pattern 1, sieve like or loose cribriform structures; Pattern 2, solid or dense cribriform structures. The purpose of the study is to identify the impact of IDC-P and its subtypes on the prognosis of patients undergoing post-operative radiotherapy (PORT) after radical prostatectomy (RP) due to localized prostate cancer(PCa). Methods We performed a retrospective study of patients with localized PCa treated by RP followed by PORT or not. Patients with localized PCa who underwent RP from August 2013 to December 2020 were included in this study. Inclusion criteria: post-operative PSA dropped to less than 0.1 ng/ml after RP, had at least 1 poor prognostic risk factor (including high Gleason’s grouping; positive surgical margins; seminal vesicle invasion; extraprostatic extension; and lympho-vascular invasion), and were eligible for adjuvant radiotherapy.; In this study, patients who underwent salvage radiotherapy after RP due to biochemical recurrence (two consecutive PSA > 0.2 ng/ml) were also included, but not patients with persistent postoperative PSA > 0.1 ng/ml. Exclusion criteria: patients using other types of therapy prior to biochemical recurrence. Screening cases with pathological results of intraductal carcinoma, subtyping was completed by a pathologist, grouped by intraductal carcinoma (+/-; pattern 1/ 2) and treatment regimen (RP + PORT / RP only), Kaplan-Meier curves were plotted based on the time to biochemical recurrence-free and overall survival of the patients, and Cox regression analyses were performed. Finally, based on the results of Cox regression analysis, we initially predicted the probability of biochemical recurrence and death of the patients by plotting the nomogram. Results A total of 139 patients were included in this study with a median follow-up of 61.5 months. K-M curves showed that patients with “IDC-P (+) RP only” had the worst prognosis; patients with IDC-P could have a survival benefit after receiving PORT; whereas patients with non-intraductal carcinoma had a better prognosis than the above patients with or without PORT. In addition, patients with IDC-P(+) pattern 2 were more likely to experience biochemical recurrence and death. Multivariate Cox regression analysis showed that pattern 2 was a risk factor for biochemical recurrence and death. Other BCR-related risk factors in the research: Gleason grading group 5 (HR = 3.343, 95% CI: 1.616–6.916, P = 0.001), PM (HR = 2.124, 95% CI: 1.044–4.320,P = 0.038) and PORT (HR = 0.266, 95%CI: 0.109–0.647, P = 0.004). Other OS-related risk factors in the research: Grading group 5 (HR = 3.642, 95%CI:1.475–8.991, P = 0.005), SVI (HR = 2.522, 95% CI: 1.118–5.691, P = 0.026) and PORT (HR = 0.319, 95%CI: 0.107–0.949, P = 0.040). Conclusion Patients suffering from localized prostate cancer with IDC-P(+), especially IDC-P pattern 2, are more susceptible to biochemical recurrence and death after radical prostatectomy. While postoperative radiotherapy can alleviate the negative prognostic impact from IDC-P. It is implied that IDC-P can also be an indicator to be considered in PORT decision making to some extent.https://doi.org/10.1186/s12894-025-01690-1Prostate cancerIntraductal carcinomaRadiotherapy
spellingShingle Fang Cao
Qing Li
Tianyu Xiong
Yingjie Zheng
Tian Zhang
Mulan Jin
Liming Song
Nianzeng Xing
Yinong Niu
Prognostic value of intraductal carcinoma subtypes and postoperative radiotherapy for localized prostate cancer
BMC Urology
Prostate cancer
Intraductal carcinoma
Radiotherapy
title Prognostic value of intraductal carcinoma subtypes and postoperative radiotherapy for localized prostate cancer
title_full Prognostic value of intraductal carcinoma subtypes and postoperative radiotherapy for localized prostate cancer
title_fullStr Prognostic value of intraductal carcinoma subtypes and postoperative radiotherapy for localized prostate cancer
title_full_unstemmed Prognostic value of intraductal carcinoma subtypes and postoperative radiotherapy for localized prostate cancer
title_short Prognostic value of intraductal carcinoma subtypes and postoperative radiotherapy for localized prostate cancer
title_sort prognostic value of intraductal carcinoma subtypes and postoperative radiotherapy for localized prostate cancer
topic Prostate cancer
Intraductal carcinoma
Radiotherapy
url https://doi.org/10.1186/s12894-025-01690-1
work_keys_str_mv AT fangcao prognosticvalueofintraductalcarcinomasubtypesandpostoperativeradiotherapyforlocalizedprostatecancer
AT qingli prognosticvalueofintraductalcarcinomasubtypesandpostoperativeradiotherapyforlocalizedprostatecancer
AT tianyuxiong prognosticvalueofintraductalcarcinomasubtypesandpostoperativeradiotherapyforlocalizedprostatecancer
AT yingjiezheng prognosticvalueofintraductalcarcinomasubtypesandpostoperativeradiotherapyforlocalizedprostatecancer
AT tianzhang prognosticvalueofintraductalcarcinomasubtypesandpostoperativeradiotherapyforlocalizedprostatecancer
AT mulanjin prognosticvalueofintraductalcarcinomasubtypesandpostoperativeradiotherapyforlocalizedprostatecancer
AT limingsong prognosticvalueofintraductalcarcinomasubtypesandpostoperativeradiotherapyforlocalizedprostatecancer
AT nianzengxing prognosticvalueofintraductalcarcinomasubtypesandpostoperativeradiotherapyforlocalizedprostatecancer
AT yinongniu prognosticvalueofintraductalcarcinomasubtypesandpostoperativeradiotherapyforlocalizedprostatecancer